Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | February 04, 2013

Game-Changing Technologies to Watch in 2013

My job as editor of DAIC is to help readers keep tabs on the latest in cardiovascular technology and trends. With collaboration from my Editorial Advisory Board, we developed a 2013 editorial calendar based on several predictions on what will be the key game-changing technologies.  These were determined from observations at numerous cardiology meetings we attended and from needs or trends members of the board have seen in their own practices. Here are our top predictions:

Fractional flow reserve (FFR) is becoming more popular because of sound clinical trial data that continues to be reinforced, its inclusion in treatment guidelines and for its potential to save money by reducing the number of stents implanted. Current iterations of the catheter-based technology can be time-consuming and require use of adenosine, which has limited adoption. A new method called IFR may greatly simplify, reduce time and eliminate the need for adenosine. A second technology showing great promise is computed tomography (CT)–FFR, which measures the FFR for all coronary vessel segments noninvasively and allows placement of virtual stents to measure their hemodynamic impact. 

Stage 2 meaningful use requirements will greatly impact cardiovascular information systems (CVIS). Stage 2 calls for clinical decision support, which will likely be seen in the form of overlay software to double-check if appropriate use criteria is being followed and to red-flag instances when it is not. Other requirements call for simplified image sharing both inside and outside hospitals, and computerized physician order entry (CPOE). Patient participation is also required, possibly by having them access information or share clinical updates via website interfaces, especially in the case of heart failure and EP implantable device followups.

New ICD technology with the new subcutaneous ICD systems offer a much simplified implant procedure and the potential to greatly reduce complications.  The results of the MADIT-RIT trial will likely make ICDs more effective by changing the way the devices are programmed. 

Hemodynamic support devices are seeing a lot of movement with the introduction of a new 5 LPM percutaneous ventricular assist device (PVAD), a new trial examining a PVAD’s impact on infarct size, FDA review of intra-aortic balloon pumps, and the increasing use of mobile extracorporeal membrane oxygenation (ECMO) units, especially in the hybrid OR.

Near-infrared spectroscopy intravascular imaging may offer a vulnerable plaque detection tool to preemptively stent potential STEMI lesions.  

Renal denervation therapy has gone from a sideshow session at meetings into the mainstream, with major vendors now making investments. 

Several of these topics are covered in the Jan/Feb 2013 issue of DAIC.

Related Content

An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.

An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.

Feature | Renal Denervation | May 30, 2018
May 30, 2018 — Despite the best efforts of clinicians to manage hypertension, it continues to increase and is now rea
Paradise Renal Denervation System Shows Significant Blood Pressure Reduction in Hypertensive Patients. PCR, #euroPCR 2018
News | Renal Denervation | May 30, 2018
ReCor Medical announced that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a...
Renal Denervation Shows Significant Drop in Hypertension
News | Renal Denervation | May 23, 2018
At the 2018 EuroPCR Annual Meeting in Paris, Medtronic announced first-ever-data from the SPYRAL HTN-ON MED Study....
Medtronic Announces Renal Denervation Pivotal Trial for Hypertension Treatment
News | Renal Denervation | April 16, 2018
Medtronic plc announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (...
SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation
News | Renal Denervation | August 31, 2017
Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial following positive first...
News | Renal Denervation | October 11, 2016
Awards from the National Institutes of Health’s Common Fund are supporting research on the peripheral nervous system,...
Technavio report, renal denervation devices, 2015
News | Renal Denervation | August 23, 2016
August 23, 2016 — Technavio analysts forecast the global...
renal denervation, resistant hypertension, rat study, American Journal of Physiology
News | Renal Denervation | February 17, 2016
February 17, 2016 — Up to 10 percent of people with high blood pressure have...
Videos | Renal Denervation | November 03, 2015
Robert Schwartz, M.D., medical director at the Minnesota Heart Institute, explains new applications for denervation t
Overlay Init